WASHINGTON — The Food and Drug Administration is wrestling with how to decide when Americans should seek out a booster dose of the single-shot Johnson & Johnson COVID-19 vaccine.
Other manufacturers propose to offer boosters six month after primary vaccination. J&J suggested a range of times from two to six months.
FDA scientists did not reach a definitive conclusion in Wednesday’s review, citing J&J’s data.
Researchers wrote that, although FDA has not confirmed the results from the datasets, summary data suggests there may be a benefit to a second dose approximately two months after the first dose. This is in comparison to the efficacy of COV3001, which was published Wednesday in a 54-page document.
According to CNBCAccording to the report, a single dose J&J vaccine “still provides protection against severe COVID-19 death and disease in the United States.”
An FDA advisory panel will make a recommendation on Thursday and Friday about whether boosters of the J&J as well as Moderna vaccines should be approved.
Moderna claimed Tuesday that it needed a third dose after the second dose. The New York TimesReports
FDA and CDC are both in agreement already approved booster shotsThe Pfizer COVID-19 vaccine is recommended for those 65 years old and over, as well as people with underlying conditions or who work in essential jobs. These Americans should seek out a Pfizer booster six to eight months after receiving their second dose, according to the FDA.